Ehlers-Danlos Syndrome vs. Marfan Syndrome

Comparing and Contrasting Ehlers-Danlos Syndrome (EDS) and Marfan Syndrome

Ehlers-Danlos Syndrome (EDS) and Marfan Syndrome (MFS) are both connective tissue disorders that affect multiple systems in the body, particularly the skin, joints, and cardiovascular system. Despite their similarities, the underlying causes, clinical presentations, and management strategies differ significantly. This article explores the key differences and commonalities between these two conditions, including the distinctive feature of marfanoid habitus.

1. Genetic Origins and Pathogenesis

Ehlers-Danlos Syndrome (EDS) is a group of genetic disorders primarily caused by mutations affecting collagen synthesis and structure. The various subtypes of EDS are associated with mutations in different genes responsible for the production or regulation of collagen, a key protein in connective tissues. For example:

• Classical EDS is linked to mutations in the COL5A1 or COL5A2 genes, while
• Vascular EDS involves mutations in COL3A1, which encodes type III collagen.
• However, the most common subtype, hypermobility EDS (hEDS), has no identified genetic marker to date.

In contrast, Marfan Syndrome (MFS) results from mutations in the FBN1 gene, which encodes fibrillin-1, a protein essential for the formation of elastic fibers. These mutations disrupt the structural integrity of connective tissues, particularly in the cardiovascular system. Additionally, Marfan Syndrome involves abnormal signaling pathways, particularly the TGF-beta signaling pathway, which influences tissue development.

2. Clinical Features

Ehlers-Danlos Syndrome (EDS) is characterized by joint hypermobility, skin hyperextensibility, and tissue fragility. The severity and range of symptoms vary depending on the subtype. For example:

• Vascular EDS involves fragile blood vessels, which can lead to life-threatening complications such as arterial rupture.
• hEDS patients frequently experience joint dislocations, chronic musculoskeletal pain, and gastrointestinal disorders like irritable bowel syndrome (IBS) and gastroesophageal reflux disease (GERD). Other common signs include easy bruising, atrophic scars, and poor wound healing.

Marfan Syndrome (MFS) is distinguished by skeletal abnormalities, such as:

• Tall stature,
• Long limbs (arachnodactyly), and
• Spinal deformities like scoliosis and pectus excavatum (sunken chest).Patients also frequently experience lens dislocation (ectopia lentis), which affects vision. However, the most critical complication of MFS is aortic root dilation, which can lead to aortic dissection or rupture if left untreated.

3. Gastrointestinal Manifestations

Both conditions can affect the gastrointestinal (GI) system, though the nature and severity differ:

• In EDS, particularly hEDS, functional gastrointestinal disorders (FGDs) like IBS, chronic constipation, and heartburn are common. GI involvement is reported in up to 75% of EDS patients.
• Marfan Syndrome patients may also experience GI symptoms like abdominal pain, constipation, and diarrhea, but these are typically less frequent and severe compared to EDS.

4. Cardiovascular Complications

The cardiovascular risks associated with EDS and Marfan Syndrome are perhaps the most life-threatening aspects of these conditions:

• In Vascular EDS, there is a high risk of arterial rupture, especially in the aorta, intestines, and uterus during pregnancy. These spontaneous ruptures can be fatal, making early diagnosis and careful monitoring essential.
• Marfan Syndrome is notorious for its risk of aortic dilation and dissection, the leading cause of mortality in untreated patients. Surgical intervention, such as aortic root replacement, is often necessary to prevent life-threatening events.

5. Musculoskeletal Differences

EDS and Marfan Syndrome both involve the musculoskeletal system, but their presentations differ:

• EDS patients, particularly those with hEDS, often suffer from severe joint hypermobility, leading to frequent joint dislocations, chronic pain, and early-onset osteoarthritis.
• Marfan Syndrome presents with more pronounced skeletal deformities, including long, slender limbs and spinal issues like kyphosis and scoliosis. While joint hypermobility is present, it is typically less severe than in EDS.

6. Marfanoid Habitus

Marfanoid habitus refers to physical characteristics similar to Marfan Syndrome, such as tall stature, long limbs, and arachnodactyly, but it can also appear in other connective tissue disorders like EDS. Individuals with marfanoid habitus may not meet the full diagnostic criteria for Marfan Syndrome.

In EDS, particularly the hypermobility or kyphoscoliosis subtypes, patients may exhibit marfanoid features like long limbs and spinal deformities without the associated cardiovascular complications seen in Marfan Syndrome.

Other conditions that exhibit marfanoid habitus include:

• Loeys-Dietz Syndrome, which involves arterial tortuosity and craniofacial abnormalities,
• Homocystinuria, a metabolic disorder with intellectual disability and lens dislocation, and
• Shprintzen-Goldberg Syndrome, which features craniosynostosis and intellectual disabilities.

7. Diagnostic Criteria

Diagnosing EDS often involves clinical features and, for some subtypes, genetic testing. The Beighton score is commonly used to assess joint hypermobility. However, hEDS remains a clinical diagnosis as no genetic marker has been identified.

Marfan Syndrome diagnosis follows the Ghent criteria, which incorporate features from various organ systems, including the skeletal, cardiovascular, and ocular systems. Genetic testing for FBN1 mutations can confirm the diagnosis but is not always required if clinical criteria are met.

8. Management Approaches

Managing EDS focuses on symptom control, including:

• Physical therapy to stabilize joints,
• Pain management, and
• Protective measures to prevent skin injuries.

For vascular EDS, regular monitoring is crucial to avoid life-threatening arterial ruptures.

Marfan Syndrome management centers on preventing aortic dissection. Beta-blockers and angiotensin receptor blockers (ARBs) are commonly prescribed to slow aortic enlargement. Surgical intervention, such as aortic root replacement, may be necessary to prevent fatal complications.

9. Prevalence in the Population

EDS and Marfan Syndrome are both rare conditions, though their exact prevalence varies:

• EDS affects 1 in 5,000 to 1 in 20,000 people globally. hEDS is the most common subtype, though estimates suggest 1 in 3,000 to 5,000 people may be affected. Vascular EDS is rarer, occurring in 1 in 50,000 to 200,000.
• Marfan Syndrome affects approximately 1 in 5,000 people worldwide. About 25% of cases result from spontaneous mutations with no family history.

10. Michael Phelps and Marfanoid Habitus

A prominent example of marfanoid habitus in the general population is Michael Phelps, the most decorated Olympian in history. Phelps' long limbs, flexible joints, and extraordinary body proportions contributed to his swimming prowess. These characteristics raised concerns that he might have Marfan Syndrome.

In his book, Michael Phelps: Beneath the Surface, he describes how his coach encouraged him to get tested at Johns Hopkins University for Marfan Syndrome due to his physical traits. Phelps recalls, “I had some early symptoms of Marfan syndrome, a disease that affects connective tissues and can be fatal if there is leakage to the vessels that lead to the heart.”

Fortunately, Phelps continues to be tested annually, and his tissues remain healthy. Dr. Reed Pyeritz, a Marfan specialist, noted that Phelps' features fit some criteria of Marfan Syndrome but emphasized that these traits can also appear in the general population.

Conclusion

While Ehlers-Danlos Syndrome (EDS) and Marfan Syndrome (MFS) share characteristics of connective tissue fragility, their genetic causes, clinical presentations, and associated risks differ significantly. EDS primarily affects the skin, joints, and gastrointestinal system, while Marfan Syndrome poses the greatest risks to the cardiovascular system, particularly the aorta. Accurate diagnosis, including attention to marfanoid habitus, and tailored management are essential for improving patient outcomes and preventing life-threatening complications.

References:

1. Callewaert, B., Malfait, F., Loeys, B., & De Paepe, A. (2008). Ehlers-Danlos syndromes and Marfan syndrome. Best Practice & Research Clinical Rheumatology, 22(1), 165–189.
2. Inayet, N., Hayat, J. O., Kaul, A., Tome, M., Child, A., & Poullis, A. (2018). Gastrointestinal Symptoms in Marfan Syndrome and Hypermobile Ehlers-Danlos Syndrome. Gastroenterology Research and Practice, Article ID 4854701, 8 pages.
3. Phelps, M. (2016). Beneath the Surface: My Story.

‍